<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        8-222-95
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1995
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OLFEN-75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DICLOFENAC SODIUM,LIDOCAINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75,20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Haupt Pharma Wulfing GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Haupt Pharma Wulfing GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACINO PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Diclofenac sodium, the active ingredient in Olfen 75 mg IM, is one of a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs reduce pain and inflammation. Olfen 75 mg IM also contains lidocaine 20 mg to reduce pain at the injection site.&nbsp;<br />&nbsp;<br />&nbsp;</p><p dir="ltr">The intramuscular injection is used to treat a number of painful conditions including:&nbsp;</p><p dir="ltr"> &nbsp; &#39;Flare-ups&#39; of joint or back pain</p><p dir="ltr"><sub>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub>Attacks of gout</p><p dir="ltr"><sub>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub>Pain caused by kidney stones</p><p dir="ltr"><sub>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub>Pain, inflammation and swelling following injuries and surgery</p><p dir="ltr"><sub>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sub>Severe migraine attacks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Olfen 75 mg IM can be given as an injection into the muscle.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Olfen 75 mg IM is not suitable for children.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">a. Don&rsquo;t take Olfen 75 mg IM if:&nbsp;<br />&nbsp;<br />&nbsp;<br /> you think you may be allergic to diclofenac sodium, aspirin, ibuprofen or any other NSAID, or to any of the other ingredients of Olfen 75 mg IM. (These are listed at the end of the leaflet.) Signs of a hypersensitivity reaction include swelling of the face and mouth (angioedema), breathing problems, runny nose, skin rash or any other allergic type reaction &nbsp; you have now, or have ever had, a stomach (gastric) or duodenal (peptic) ulcer, or bleeding in the digestive tract (this can include blood in vomit, bleeding when emptying bowels, fresh blood in faeces or black, tarry faeces)  you have had stomach or bowel problems after you have taken other NSAIDs &nbsp; you have moderate or severe heart, kidney or liver failure  if you have established heart disease and/or cerebrovascular disease e.g. if you have had a heart attack, stroke, mini-stroke (TIA) or blockages to blood vessels to the heart or brain or an operation to clear bypass blockages  if you have or have had problems with your blood circulation (peripheral arterial disease)  you are more than six months pregnant&nbsp;<br />&nbsp;<br />b. Take special care with Olfen 75 mg IM if you:&nbsp;<br />&nbsp; suffer from any bowel disorders including ulcerative colitis or Crohn&#39;s disease  have kidney or liver problems, or are you elderly &nbsp; suffer from any blood or bleeding disorder  have a condition called porphyria &nbsp;  ever had asthma  breastfeeding &nbsp; have angina, blood clots, high blood pressure, raised cholesterol or raised triglycerides &nbsp;  have heart problems, or have you had a stroke, or do you think you might be at risk of these conditions (for example, if you have high blood pressure, diabetes or high cholesterol or are a smoker) &nbsp;  have diabetes &nbsp; smoke &nbsp;  have Lupus (SLE) or any similar condition &nbsp; be suffering from dehydration &nbsp; suffered any heavy loss of blood recently&nbsp;<br />&nbsp;<br />c. Other special warnings&nbsp;<br />&nbsp; You should take the lowest dose of Olfen 75 IM for the shortest possible time, particularly if you are underweight or elderly. &nbsp; There is a small increased risk of heart attack or stroke when you are taking any medicine like Olfen 75 IM. The risk is higher if you are taking high doses for a long time. Always follow the doctor&rsquo;s instructions on how much to take and how long to take it for. &nbsp;  Whilst you are taking these medicines your doctor may want to give you a check-up from time to time. &nbsp; If you have a history of stomach problems when you are taking NSAIDs, particularly if you are elderly, you must tell your doctor straight away if you notice any unusual symptoms.  Because it is an anti-inflammatory medicine, Olfen 75 IM may reduce the symptoms of infection, for example, headache and high temperature. If you feel unwell and need to see a doctor, remember to tell him or her that you are taking Olfen 75 IM. &nbsp; Olfen 75 mg IM should not be used in children. &nbsp;<br />&nbsp;<br />d. Taking other medicines with Olfen 75 mg IM &nbsp;<br />&nbsp;Some medicines can interfere with your treatment. Tell your doctor or pharmacist if you are taking any of the following:&nbsp;<br />&nbsp; Medicines to treat diabetes &nbsp;  Anticoagulants (blood thinning tablets like warfarin) Diuretics (water tablets) &nbsp;  Lithium (used to treat some mental problems) &nbsp;  Methotrexate (for some inflammatory diseases and some cancers) &nbsp;  Ciclosporin and tacrolimus (used to treat some inflammatory diseases and after transplants) &nbsp;  Trimethoprim (a medicine used to prevent or treat urinary tract infections) Quinolone antibiotics (for infections) &nbsp;  Any other NSAID or COX-2 (cyclo-oxgenase-2) inhibitor, for example aspirin or ibuprofen &nbsp;  Mifepristone (a medicine used to terminate pregnancy) &nbsp;  Cardiac glycosides (for example digoxin), used to treat heart problems &nbsp; Medicines known as SSRIs used to treat depression  Oral steroids (an anti-inflammatory drug) &nbsp;  Medicines used to treat heart conditions or high blood pressure, for example betablockers or ACE inhibitors. &nbsp;  Voriconazole (a medicine used to treat fungal infections).  Phenytoin (a medicine used to treat seizures) &nbsp;  Colestipol/cholestyramine (used to lower cholesterol) &nbsp;<br />&nbsp;<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&nbsp;<br />&nbsp;<br />e. Pregnancy, breast-feeding &nbsp;<br />&nbsp;<br />&nbsp;<br /> Are you pregnant or planning to become pregnant? Although not common, abnormalities have been reported in babies whose mothers have taken NSAIDs during pregnancy. You should not have a Olfen injection during the last 3 months of pregnancy as it may affect the baby&rsquo;s circulation. &nbsp;  Are you trying for a baby? Having Olfen injections may make it more difficult to conceive. You should talk to your doctor if you are planning to become pregnant, or if you have problems getting pregnant. &nbsp;<br />&nbsp;<br />f. Driving and using machines&nbsp;<br />&nbsp;<br />Very occasionally people have reported that Olfen 75 mg IM have made them feel dizzy, tired or sleepy. Problems with eyesight have also been reported. If you are affected in this way, you should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Your doctor will decide when and how to treat you with Olfen 75 mg IM. The intramuscular injection is usually injected into the buttocks.&nbsp;<br />&nbsp;<br />The usual dose is: Adults&nbsp;<br />&nbsp;One or two ampoules (75 to 150 mg) each day for one or two days.&nbsp;<br />&nbsp;<br />Elderly&nbsp;<br />&nbsp;Your doctor may give you a dose that is lower than the usual adult dose if you are elderly.&nbsp;<br />&nbsp;<br />Children&nbsp;<br />&nbsp;Not suitable for children.&nbsp;<br />&nbsp;<br />A doctor, nurse or pharmacist will prepare the injection for you.&nbsp;<br />&nbsp;<br />&nbsp;<br />The doctor may also prescribe another drug to protect the stomach to be taken at the same time, particularly if you have had stomach problems before, or if you are elderly, or taking certain other drugs as well.&nbsp;<br />&nbsp;<br />a. If you take more Olfen 75 mg IM than you should&nbsp;<br />&nbsp;If you think you have been given too much Olfen 75 mg IM tell your doctor or nurse straight away.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Olfen 75 mg IM are suitable for most people, but, like all medicines, they can sometimes cause side effects. Side effects may be minimised by using the lowest effective dose for the shortest duration necessary.&nbsp;<br />&nbsp;<br />Some side effects can be serious&nbsp;<br />&nbsp;Tell the doctor straight away if you notice:&nbsp;<br />&nbsp; Stomach pain, indigestion, heartburn, wind, nausea (feeling sick) or vomiting (being sick) Any sign of bleeding in the stomach or intestine, for example, when emptying your &nbsp;  bowels, blood in vomit or black, tarry faeces &nbsp;  Allergic reactions which can include skin rash, itching, bruising, painful red areas, peeling or blistering &nbsp;  Wheezing or shortness of breath (bronchospasm) Swollen, face, lips, hands or fingers &nbsp;  Yellowing of your skin or the whites of your eyes Persistent sore throat or high temperature &nbsp;  An unexpected change in the amount of urine produced and/or its appearance. &nbsp;  Mild cramping and tenderness of the abdomen, starting shortly after the start of the treatment with Olfen 75 mg IM and followed by rectal bleeding or bloody diarrhoea usually within 24 hours of the onset of abdominal pain. &nbsp;<br />&nbsp;<br />If you notice that you are bruising more easily than usual or have frequent sore throats or infections, tell your doctor.&nbsp;</p><p dir="ltr">&nbsp;The side effects listed below have also been reported.&nbsp;<br />&nbsp;<br />Common side effects (These may affect between 1 and 10 in every 100 patients):&nbsp;<br />&nbsp;Stomach pain, heartburn, nausea, vomiting, diarrhoea, indigestion, wind, loss of appetite Headache, dizziness, vertigo&nbsp;<br />&nbsp;Skin rash or spots&nbsp;<br />&nbsp;Raised levels of liver enzymes in the blood&nbsp;<br />&nbsp;Injection site reactions, symptoms include redness, swelling, change in the skin colour, inflammation, pain, and hypersensitivity&nbsp;<br />&nbsp;<br />Rare side effects (These may affect between 1 in every 1000 to 1 in every 10,000 patients):&nbsp;<br />&nbsp;Stomach ulcers or bleeding (there have been very rare reported cases resulting in death, particularly in the elderly)&nbsp;<br />&nbsp;Gastritis (inflammation, irritation or swelling of the stomach lining) Vomiting blood&nbsp;<br />&nbsp;Diarrhoea with blood in it or bleeding from the back passage Black, tarry faeces or stools&nbsp;<br />&nbsp;Drowsiness, tiredness&nbsp;<br />&nbsp;Hypotension (low blood pressure, symptoms of which may include faintness, giddiness or light headedness)&nbsp;<br />&nbsp;Skin rash and itching&nbsp;<br />&nbsp;Fluid retention, symptoms of which include swollen ankles Liver function disorders, including hepatitis and jaundice&nbsp;<br />&nbsp;Injection site necrosis (dead skin and tissue around the injection site)&nbsp;<br />&nbsp;<br />Very rare side effects (These may affect less than 1 in every 10,000 patients):&nbsp;<br />&nbsp;Effects on the nervous system:&nbsp;<br />&nbsp;Tingling or numbness in the fingers, tremor, visual disturbances such as blurred or double vision, hearing loss or impairment, tinnitus (ringing in the ears), sleeplessness, nightmares, mood changes, depression, anxiety, mental disorders, disorientation and loss of memory, fits, headaches together with a dislike of bright lights, fever and a stiff neck, disturbances in sensation.&nbsp;<br />&nbsp;<br />Effects on the stomach and digestive system:&nbsp;<br />&nbsp;Constipation, inflammation of the tongue, mouth ulcers, inflammation of the inside of the mouth or lips, taste changes, lower gut disorders (including inflammation of the colon, or worsening of colitis or Crohn&rsquo;s disease).&nbsp;<br />&nbsp;<br />Effects on the heart, chest or blood:&nbsp;<br />&nbsp;Palpitations (fast or irregular heart beat), chest pain, hypertension (high blood pressure), inflammation of blood vessels (vasculitis), inflammation of the lung (pneumonitis), heart disorders, including congestive heart failure or heart attack, blood disorders (including anaemia).&nbsp;<br />&nbsp;<br />Effects on the liver or kidneys:&nbsp;<br />&nbsp;Kidney or severe liver disorders including liver failure, presence of blood or protein in the urine.&nbsp;<br />&nbsp;<br />Effects on skin or hair:&nbsp;<br />&nbsp;Serious skin rashes including Stevens-Johnson syndrome, Lyell&rsquo;s syndrome and other skin rashes which may be made worse by exposure to sunlight.&nbsp;<br />&nbsp;Hair loss.&nbsp;<br />&nbsp;<br />Other side effects that have also been reported include:&nbsp;<br />&nbsp;<br />Inflammation of the pancreas, impotence. Facial swelling, inflammation of the lining of the brain (meningitis), stroke, throat disorders, confusion, hallucinations, malaise (general feeling of discomfort), inflammation of the nerves in the eye, tissue damage at the injection site.&nbsp;<br />&nbsp;<br />Do not be alarmed by this list - most people have an injection of Olfen 75mg IM without any problems.&nbsp;<br />&nbsp;<br />If any of the symptoms become troublesome, or if you notice anything else not mentioned here, please go and see your doctor. He/she may want to give you a different medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not store above 30&deg;C. &nbsp;Store the Olfen 75 mg IM in the original package in a dry place. &nbsp;Keep out of the reach and sight of children.&nbsp;<br />&nbsp;Do not use Olfen 75 mg IM after the expiry date which is stated on the pack.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Active substances: diclofenac sodium, lidocaine hydrochloride. &nbsp;Each 2 ml ampoule contains diclofenac sodium 75 mg, lidocaine hydrochloride 20 mg. Excipients: N-acetylcysteine, disodium edetate, macrogol 400, propylene glycol, sodium hydroxide, water for injections.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The product is filled into 2 ml amber (brown) glass ampoules (hydrolytic class I), with white OPC (One Point Cut) point.   Packs of 3 and 5 ampoules of 2 ml; hospital packs. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorization Holder Acino Pharma AG, Liesberg, Switzerland Manufacturer Manufactured by Haupt Pharma Wulfing GmbH, Gronau/Leine, Germany Batch releaser: Acino Pharma AG, Aesch, Switzerland&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This package leaflet was last revised in July 2018 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p dir="RTL">ينتمي ديكلوفيناك الصوديوم، المادة الفعالة بأولفين ٧٥ مجم للحقن العضلي، لمجموعة من الأدوية تُدعى الأدوية المضادة للالتهابات غير الستيرويدية (مضادات الالتهاب غير الستيرويدية). تعمل مضادات الالتهاب غير الستيرويدية على الحد من الألم والالتهاب.&nbsp; يحتوي أولفين ٧٥ مجم للحقن العضلي على ليدوكائين 20 مجم للحد من الألم في موضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يسُتخدم الحقن في العضل لعلاج العديد من الحالات المؤلمة بما في ذلك:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;نوبات احتدام&quot; بالمفاصل أو آلام بالظهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات النقّْرِس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم ناجم عن وجود حصى بالكُلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم والالتهاب والتورم التَّابع للإصابات والجراحة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات الصداع النصفي الشديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء أولفين ٧٥ مجم للحقن العضلي على هيئة حقن بالعضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعُد أولفين ٧٥ مجم للحقن العضلي غير مناسب للأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أولفين 75 مجم للحقن العضلي في الحالات التَّالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعتقد أنك قد تكون مصابًا بحساسية تجاه ديكلوفيناك الصوديوم، الأسبرين، إيبوبروفين أو تجاه أيٍّ من مضادات الالتهاب غير الستيرويدية الأخرى أو تجاه أي من المكونات الأخرى بأولفين ٧٥ مجم للحقن العضلي.</p><p dir="RTL">( ذلك مدرج في نهاية النَّشرة) تشمل علامات الإصابة بتفاعلات فرط الحساسية تورم الوجه والفم (وذمة وعائية)، مشاكل بالتنفس، سيلان الأنف، طفحًا جلديا أو أي نوع آخر من تفاعلات الحساسية.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني الآن أو عانيت من قبل من قرح المعدة أو الإثنا عشر (هضمية) أو نزيف بالجهاز الهضمي (قد يشمل ذلك قيئاً مصحوبًا بدم، نزيفًا عند إفراغ الأمعاء، برازًا مصحوبًا بدم جديد أو برازًا أسود قطرانيا)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من مشاكل بالبطن أو الأمعاء بعد تناولك مضادات التهاب غير ستيرويدية أخرى.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بفشل معتدل أو شديد بالقلب أو الكُلى أو الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض مؤكد بالقلب و/أو مرض بالأوعية الدَّ موية بالمخ على سبيل المثال: إذا أصُبت بنوبة قلبية، سكتة دماغية، سكتة دماغية صغرى (نوبة إقفارية عابرة) أو انسداد بالأوعية الدَّ موية المؤدية إلى القلب أو المخ أو خضعت لعملية لإزالة انسدادات المجازة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من مشاكل بالدَّورة الدَّموية لديك (أمراض الشرايين الطرفية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تجاوز حملك ستة أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; توخ حذرًا خاصا مع أولفين ٧٥ مجم للحقن العضلي في الحالات التَّالية:&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي اضطرابات بالأمعاء بما في ذلك التهاب القولون التَّقرحي أو مرض كرون.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكُلى أو الكبد أو إذا كنت من كبار السن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات دم أو نزيف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حالة تدُعى البروفيرِية.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصُبت من قبل بالربو.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تمارسين الرضاعة الطبيعية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ذبجة صدرية، جلطات دموية، ارتفاع ضغط الدَّ م، ارتفاع مستوى الكوليسترول أو الدهون الثلاثية.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالقلب أو أصُبت بسكتة دماغية أو تعتقد أنك تواجه خطر الإصابة بهذه الحالات (على سبيل المثال: إذا كنت تعاني من ارتفاع ضغط الدَّ م، مرض السكرِي أو ارتفاع مستوى الكوليسترول أو كنت مدخنًا).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السكري.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مدخنًا.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالذئبة (الذِئّبَةِ الحُمَامِيةِ الجَهازِية) أو أي حالة مماثلة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من فقدان كبير للدَّم مؤخرًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحذيرات خاصة أخرى</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك أخذ أقل جرعة من أولفين ٧٥ للحقن العضلي لأقصر فترة ممكنة، خاصة إذا كنت منخفض الوزن</p><p dir="RTL">(نحيفًا) أو من كبار السن.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك خطر متزايد بنسبة ضئيلة لاحتمال حدوث نوبة قلبية أو سكتة دماغية عند تناولك لدواء مماثل لأولفين ٧٥ للحقن العضلي. ترتفع نسبة الخطورة في حال كنت تتناول جرعات مرتفعة لفترة طويلة. اتبع دائمًا تعليمات الطبيب حول الكمية التي ينبغي تناولها ومدة الاستخدام.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يرغب طبيبك في فحصك من حين لآخر أثناء تناولك لهذه الأدوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من الإصابة بمشاكل بالمعدة أثناء تناولك لمضادات الالتهاب غير الستيرويدية، خاصة إذا كنت من كبار السن، يجب عليك إخبار طبيبك على الفور إذا لاحظت أي أعراض غير معتادة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظرًا لأنه دواء مضاد للالتهاب، قد يحد أولفين ٧٥ للحقن العضلي من أعراض العدوى، على سبيل المثال ،الصداع وارتفاع درجة الحرارة. إذا كنت تشعر بالإعياء وتحتاج إلى زيارة الطبيب(ة)، تذكر إخباره/ إخبارها بأنك تستخدم أولفين ٧٥&nbsp; للحقن العضلي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحُظر استخدام أولفين ٧٥ مجم للحقن العضلي في الأطفال.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام أدوية أخرى مع أولفين 75 مجم للحقن العضلي&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتداخل بعض الأدوية مع علاجك. أيضًا، أخبر الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أيا من الأدوية</p><p dir="RTL">التَّالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج مرض السكري.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التَّخثر (أقراص لتسييل الدَّم مثل وارفارين) مُدِرات البول (أقراص الماء).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم (يسُتخدم لعلاج بعض المشاكل العقلية).&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات (لبعض الأمراض الالتهابية وبعض أنواع السرطان).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين وتاكروليموس (يسُتخدمان لعلاج بعض الأمراض الالتهابية وبعد الخضوع لعمليات الزرع).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايميثوبريم (أحد الأدوية التي تسُتخَدمَ للوقاية من عدوى المسالك البولية أو علاجها) المضادات الحيوية من مجموعة الكينولون (لعلاج العدوى).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مضادات التهاب غير ستيرويدية أخرى أو مثبطات الأكسدة الحلقية-2، على سبيل المثال: الأسبرين أو إيبوبروفين.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميفيبريستون (دواء يستخدم لإنهاء الحمل).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكوزيدات القلب (على سبيل المثال: ديجوكسين)، تسُتخدم لعلاج مشاكل القلب.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعُرف بمثبطات إعادة امتصاص السيروتونين الانتقائية وتسُتخدمَ لعلاج الاكتئاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات الفموية (أحد العقاقير المضادة للالتهاب).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تسُتخدمَ لعلاج حالات القلب أو ارتفاع ضغط الدَّ م، على سبيل المثال: حاصرات بيتا أو مُثبطات إنزيم تحويل الأنجيوتنسين.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوريكونازول (دواء يستخدم لعلاج العدوى الفطرية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (دواء يسُتخدم لعلاج التشنجات).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - كوليستيبول/ كولستيرامين- يسُتخدمَ لخفض مستويات الكوليسترول.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرُجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أية أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمل والرضاعة الطبيعية&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل أنت حامل أو تعتزمين الحمل؟ على ال َّرغم من أنه غير شائع، إ َّلِا إنه تم الإبلاغ عن تشوهات في الأطفال الذين تناولت أمهاتهم مضادات الالتهاب غير الستيرويدية أثناء الحمل. ينبغي عدم تلقي حُقن أولفين&nbsp; خلال الأشهر الثلاثة الأخيرة من الحمل فقد يؤُثر على الدَّ ورة الدَّ موية للجنين.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تحاولين الإنجاب؟ قد تتسبب حُقن أولفين في زيادة صعوبة حدوث حمل. يجب عليكِ إخبار طبيبك إذا كنتِ تخططين للحمل أو إذا كان لديكِ مشاكل في أن تصبحي حاملًا .&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيادة واستخدام الآلات</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد أبلغ بعض الأشخاص بأن أولفين ٧٥ مجم للحقن العضلي قد تسَ َّ بب في شعورهم بدوخة، إرهاق أو نعاس وذلك بشكل نادر للغاية. تم الإبلاغ أيضًا عن مشاكل بالرؤية. إذا حدث لك ذلك، فلا تمارس القيادة أو تشغل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك متى وكيفية علاجك باستخدام أولفين 75 مجم للحقن العضلي. عادة ما يتم حقن الحُقن العضلية في الأرداف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة هي:</p><p dir="RTL">&nbsp; البالغون&nbsp;</p><p dir="RTL">أمبولة واحدة أو أمبولتان (75 إلى 150 مجم) كل يوم لمدة يوم أو يومين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;كبار السن&nbsp;</p><p dir="RTL">قد يعطيك طبيبك جرعة أقل من جرعة البالغين المعتادة إذا كنت من كبار السن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال&nbsp;</p><p dir="RTL">غير مناسب للأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيُعد طبيب أو ممرض أو صيدلي الحَقن لك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;قد يصف الطبيب أيضًا عقارًا آخر لحماية المعدة وسيتم تناوله في الوقت ذاته، خاصة إذا عانيت سابقًا من مشاكل بالمعدة أو إذا كنت من كبار السن أو إذا كنت تتناول عقاقير أخرى معينة بالتَّزامن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;أ. إذا استخدمت كمية من أولفين 75 مجم للحقن العضلي أكثر مما يجب</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تظن أنك تلقيت كمية كبيرة للغاية من أولفين ٧٥ مجم للحقن العضلي، فاتصل بطبيبك أو الممرض على الفور.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يعُد أولفين ٧٥ مجم للحقن العضلي مناسبًا لأغلب الأشخاص، لكن، مثله مثل كافة الأدوية، قد يسبب أحيانًا آثارًا جانبية.</p><p dir="RTL">ويمكن الحد من الآثار الجانبية باستخدام أقل جرعة فعالة لأقصر مدة لازمة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>بعض الآثار الجانبية قد تكون خطيرة</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الطبيب على الفور إذا لاحظت أيا من الآتي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا بالمعدة، عسر هضم، حموضة (حُرْقَة الفُؤاد)، ريحًا، الغثيان (شعورًا بالإعياء) أو قيئًا (إعياء) أي علامة تشُير إلى وجود نزيف بالمعدة أو الأمعاء، على سبيل المثال: عند إفراغ أمعائك&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ، قيء مصحوب بدم أو براز أسود، قطراني&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية قد تشمل طفحًا جلديا، حكة، كدمات، مناطق حمراء بها ألم، تقشر أو ظهور بثور.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيزًا بالصدر أو ضيق النفس (تشنُّ جًا قَصَبيا)/ تورم الوجه، الشفتين، اليدين أو الأصابع.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار جلدك أو بياض عينيك، التهابًا مستمرا بالحلق أو ارتفاع درجة الحرارة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرًا غير متوقع في كمية البول الذي تم إنتاجه و/أو شكله.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات وأوجاع بسيطة بالبطن، تبدأ بعد فترة قصيرة من بدء العلاج بأولفين ٧٥ مجم للحقن العضلي ويليه نزيف من المستقيم أو إسهال مصحوب بدم عادة خلال ال24 ساعة الأولى من بدء آلام البطن.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أنك تصُاب بكدمات بشكل أسهل من المعتاد أو كنت تعاني مرارًا من التهابات بالحلق أو عدوى، فأخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تم أيضًا الإبلاغ عن الآثار الجانبية المدرجة أدناه.</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤُثر في ما بين ١ و ١٠ في كل ١٠٠ مريض):</p><p dir="RTL">&nbsp;</p><p dir="RTL">ألم بالمعدة، حموضة (حُرْقَة الفُؤاد)، غثيان، قيء، إِسْهال، عُسْر هَضْم، ريح، فقدان الشهية، صداع، دوخة، دوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">طفح جلدي أو بقع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ارتفاع مستويات إنزيمات الكبد بالدَّ م.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تفاعلات بموضع الحقن، أعراض تشمل الاحمرار والتورم وتغير لون الجلد والالتهاب والألم وفرط الحساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية النادرة (قد تؤُثر في ما بين 1 في كل 1000 مريض إلى 1 في كل 10,000 مريض):</p><p dir="RTL">&nbsp;</p><p dir="RTL">قرح أو نزيف بالمعدة (تم الإبلاغ عن حالات نتج عنها الوفاة، خاصة في كبار السن، بشكل نادر للغاية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب المعدة (التهاب، تهيُّج أو تورم بطانة المعدة) قيء دموي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إسهال مصحوب بدم أو نزيف من الممر الخلفي، براز أسود أو قطراني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نعاس، إرهاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انخفاض ضغط الدَّ م (قد تشمل الأعراض إغماءً، دوخة أو دوارًا بالرأس).</p><p dir="RTL">&nbsp;</p><p dir="RTL">طفح جلدي وحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتباس السوائل، تشمل الأعراض تورم الكاحلين، اضطرابات بوظائف الكبد، بما في ذلك التهاب الكبد واليرقان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نخر بموضع الحقن (موت الجلد والأنسجة حول موضع الحقن).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية ال َّ نادرة جدا (قد تؤُثر في أقل من 1 في كل 10,000 مريض).</p><p dir="RTL">&nbsp;<u>التَّأثيرات على الجهاز العصبي:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">وخز أو تنميل بالأصابع، ارتعاش، اضطرابات بصرية مثل: عدم وضوح الرؤية أوازدواجها، فقدان السمع أو ضعفه ،طنين بالأذن، عدم القدرة على النوم (أرق)، كوابيس، تغيرات في المزاج، اكتئاب، قلق، اضطرابات عقلية، توهان وفقدان الذاكرة، نوبات تشنجية، صداع مصحوب بانزعاج من الأضواء الساطعة، حُمّى وتصلب العنق، اضطرابات بالإحساس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التَّأثيرات على المعدة والجهاز الهضمي:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">إمساك، التهاب اللسان، قرح بالفم، التهاب الجزء الدَّ اخلي من الفم أو الشفتين، تغيرات بالمذاق، اضطرابات بالجزء السفلي من الأمعاء (بما في ذلك التهاب القولون أو تفاقم التهاب القولون أو مرض كرون).</p><p dir="RTL">&nbsp;<u>التَّأثيرات على القلب، الصدر أو الدَّم:</u></p><p dir="RTL">&nbsp;خَفَقان (تسارع أو عدم انتظام ضربات القلب)، ألم بالصدر، ارتفاع ضغط الدَّم، التهاب الأوعية الدَّموية، الالتهاب الرئوي ،اضطرابات بالقلب، بما في ذلك: فشل القلب الاحتقاني أو نوبة قلبية، اضطرابات بالدَّ م (بما في ذلك فقر الدَّم/ الأنيميا).</p><p dir="RTL">&nbsp;<u>التَّأثيرات على الكبد أو الكُلى:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">اضطرابات شديدة بالكُلى أو الكبد بما في ذلك: فشل الكبد، وجود دم أو بروتين بالبول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التَّأثيرات على الجلد أو الشعر:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">طفح جلدي خطير بما في ذلك: متلازمة ستيفنز جونسون، متلازمة لايل وغيرهما من الطفح الجلدي والذي قد يتفاقم نتيجة التعرض لأشعة الشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تساقط الشعر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تم أيضًا الإبلاغ عن آثار جانبية أخرى تتضمن الآتي:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب البنكرياس، عُنَّة (اضطرابات الانتصاب). تورم الوجه، التهاب بطانة المخ (الْتِهاب السّحَايَا)، سكتة دماغية ،اضطرابات الحلق، ارتباكًا/ التباسًا، هلاوس، توَعكًا (شعورًا عاما بالانزعاج)، التهاب الأعصاب بالعين، تلفًا بالأنسجة في موضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تخف من هذه القائمة -يتم حقن أغلب الأشخاص بأولفين 75 مجم للحقن العضلي دون أي مشاكل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تفاقمت أي من الأعراض أو إذا لاحظت أي شيء غير مذكور هنا، يرُجى زيارة الطبيب/ الطبيبة الخاص(ة) بك. قد يرغب/ ترغب في إعطائك دواءً مختلفًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يخُزن في درجة حرارة تتعدى 30 درجة مئوية.&nbsp;</p><p dir="RTL">يحُفظ أولفين 75 مجم للحقن العضلي في العبوات الأصلية في مكان جافٍّ .&nbsp;</p><p dir="RTL">يحُفظ بعيداً عن مُتناوَل ورؤية الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يسُتخدمَ أولفين 75 مجم للحقن العضلي بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة: ديكلوفيناك الصوديوم، هيدروكلوريد الليدوكائين.&nbsp; يحتوي كل أمبول بحجم 2 مللي لتر على ديكلوفيناك الصوديوم 75 مجم، هيدروكلوريد الليدوكائين 20 مجم.</p><p dir="RTL">السواغات (المواد غير الفعالة): إن-أسِتيل سيسْتيين، ثنائي إيديتات الصوديوم، ماكروجول 400، جليكول البروبيلين ،هيدروكسيد الصوديوم، ماء للحقن.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتم تعبئة المنتج في أمبولات زجاجية كهرمانية (بنية) اللون بحجم 2 مللي لتر (مقامة للتحلل المائي من الفئة الأولى)، بها علامة واحدة ذات لون أبيض لكسر الأمبول (OPC).&nbsp;&nbsp;</p><p dir="RTL">عبوات تحتوي على 3 و 5 أمبولات بحجم 2 مللي لتر: عبوات مستشفيات.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>مالك حق التَّسويق</u></p><p dir="RTL">شركة أسينو فارما إيه جي، ليزبيرج، سويسرا.</p><p dir="RTL"><u>جهة التَّصنيع</u></p><p dir="RTL">تم التَّصنيع عن طريق شركة هاوبت فارما وولفنج المحدودة، جروناو/ اللاين، ألمانيا جهة إصدار التَّشغيلة: شركة أسينو فارما إيه جي، أيسش، سويسرا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌تمت آخر مراجعة لهذه النَّشرة في يوليو 2018. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olfen TM 75 mg IM, solution for injection IM 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substances: diclofenac sodium, lidocaine hydrochloride.  Excipients: N-acetylcysteine, disodium edetate, macrogol 400, propylene glycol, sodium hydroxide, water for injections.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection IM  Clear colourless to slightly yellow solution in 2 ml amber glass ampoules. Each 2 ml ampoule contains diclofenac sodium 75 mg, lidocaine hydrochloride 20 mg. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Intramuscular injection &nbsp;Initial treatment for the following conditions: &nbsp;&minus; Exacerbation of inflammatory or degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis, painful vertebral syndromes, extra-articular rheumatism.</p><p dir="ltr">&minus; Acute attacks of gout.</p><p dir="ltr">&nbsp;&minus; Renal and billiary collic.</p><p dir="ltr">&minus; Pain, inflammation and swelling following injury and surgery</p><p dir="ltr">&minus; Severe migraine attacks.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Generally it is advisable to select the dose on an individualised basis. Adverse reactions can be reduced by administering the lowest effective dose over the shortest possible time for symptomatic control (see &ldquo;Warnings and precautions&rdquo;). &nbsp;<br />&nbsp;<br />Adults Treatment with Olfen ampoules should not last more than 2 days and can be continued, if necessary, with Olfen film-coated tablets or Olfen rectal capsules.&nbsp;<br />&nbsp;<br />Intramuscular injection &nbsp;The following instructions for intramuscular administration must be followed to avoid damage to nerves or other tissues at the injection site (which may lead to muscle weakness, muscle paralysis and hypoaesthesia). &nbsp;The general dosage is one 75 mg ampoule/day, administered under aseptic conditions by deep intragluteal injection into the upper outer quadrant. &nbsp;In severe cases (such as colic), two 75 mg ampoules/day may also be given exceptionally, by injecting one on the left side and one on the right side with an interval of a few hours in between. However, one 75 mg ampoule can also be combined with other pharmaceutical forms of Olfen (e.g. film-coated tablets, prolonged-release capsules, prolonged-release tablets, rectal capsules) up to a maximum total daily dose of 150 mg. &nbsp;Clinical experience of use in migraine attacks is limited to the following procedure: initiation of treatment as early as possible with one 75 mg ampoule and, if necessary, continuation on the same day with rectal capsules at a dose of up to 75 mg. The total dose on the first day should not exceed 150 mg. &nbsp;No data are available on the use of Olfen as a migraine treatment for duration of more than one day. Should treatment need to be continued on the following days, the daily dose should be limited to a maximum of 150 mg (as rectal capsules divided into single doses).&nbsp;<br />&nbsp;<br />Intravenous infusion &nbsp;Olfen must not be given as an intravenous bolus injection. &nbsp;<br />&nbsp;<br />Special dosage instructions &nbsp;Paediatric population (under 18 years) &nbsp;Given their strength, Olfen ampoules are not suitable for use in children and adolescents. &nbsp;<br />&nbsp;<br />Elderly patients (65 years and older) In general, no adjustment of the initial dose is required in elderly patients. However, due to basic medical considerations, caution is advised in elderly patients. Particularly in frail elderly patients or those with a low body weight (see &ldquo;Warnings and precautions&rdquo;).&nbsp;<br />&nbsp;<br />Existing cardiovascular disease or significant cardiovascular risk factors &nbsp;<br />Treatment with Olfen is generally not recommended in patients with existing cardiovascular disease or uncontrolled hypertension. If necessary, patients with existing cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease should not be treated with Olfen until after a careful assessment and if administered for more than 4 weeks they should not receive doses exceeding 100 mg per day (see &ldquo;Warnings and precautions&rdquo;). &nbsp;<br />&nbsp;<br />Patients with renal insufficiency &nbsp;<br />Olfen is contraindicated in patients with renal insufficiency (GFR &lt;15 ml/min/1.73 m 2 ) (see &ldquo;Contraindications&rdquo;). &nbsp;No specific studies have been conducted in patients with impaired renal function and it is therefore not possible to make specific dose adjustment recommendations. Caution is required when administering Olfen to patients with renal function impairment (see &ldquo;Warnings and precautions&rdquo;).&nbsp;<br />&nbsp;<br />Patients with hepatic impairment &nbsp;Olfen is contraindicated in patients with hepatic insufficiency (see &ldquo;Contraindications&rdquo;). &nbsp;No specific studies have been conducted in patients with impaired hepatic function and it is therefore not possible to make specific dose adjustment recommendations. Caution is required when administering Olfen to patients with mild to moderate hepatic function impairment (see &ldquo;Warnings and precautions&rdquo;). &nbsp;<br />&nbsp;<br />Instructions for use &nbsp;Olfen ampoules must be administered intramuscularly as a deep intragluteal injection in the upper outer quadrants. Each ampoule is intended for single use. The solution should be used immediately after opening. Any residual solution should be discarded.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                − Hypersensitivity to the active substance or to any of the excipients listed in the composition.  − History of bronchospasm, urticaria, acute rhinitis, nasal polyps or allergy-like symptoms after taking acetylsalicylic acid or non-steroidal anti-inflammatory drugs.  − Third trimester of pregnancy (see “Pregnancy/Lactation”).  − Active gastric and/or duodenal ulceration, or gastrointestinal haemorrhage or perforation.  − Inflammatory bowel diseases (such as Crohn's disease, ulcerative colitis).  − Hepatic insufficiency (Child-Pugh class C) (hepatic cirrhosis and ascites).  
− Renal insufficiency (GFR <15 ml/min/1.73 m 2 ).  
− Severe cardiac failure (NYHA III-IV).  − Patients with a high risk of postoperative bleeding, anticoagulation, incomplete haemostasis, haematopoietic disorders or cerebrovascular haemorrhage.  − Treatment of postoperative pain after coronary bypass surgery (or use of a heart-lung machine).  
− Children under 14 years of age.  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">General warning about the use of systemic non-steroidal anti-inflammatory drugs &nbsp;Gastrointestinal ulceration, bleeding or perforation may occur at any time during treatment with non-steroidal anti-inflammatory drugs (NSAIDs), whether COX-2 selective or not, even without warning symptoms or a relevant previous history. To minimise this risk, the lowest effective dose should be administered for the shortest possible duration. &nbsp;Placebo-controlled studies have demonstrated that certain selective COX-2 inhibitors increase the risk of thrombotic cardiovascular and cerebrovascular complications. It is not yet known whether this risk correlates directly with the COX-1/COX-2 selectivity of the individual NSAIDs. Since no comparable clinical study data are currently available on diclofenac at maximum dosage during long-term therapy, the possibility of a similarly high risk cannot be ruled out. Until relevant data are available, diclofenac should be used in clinically confirmed cases of coronary heart disease, cerebrovascular disease, peripheral arterial occlusive disease, or in patients with significant risk factors (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), only after careful consideration of the benefits and risks. The lowest effective dose should be administered for the shortest possible duration also because of this risk. &nbsp;The renal effects of NSAIDs comprise fluid retention with oedema and/or arterial hypertension. Diclofenac should therefore be used only with caution in patients with impaired cardiac function and other conditions that predispose them to fluid retention. Caution is also advised in patients taking diuretics or ACE inhibitors concomitantly, as well as in those with an increased risk of hypovolaemia. &nbsp;In the elderly, the consequences are generally more serious. If gastrointestinal bleeding or ulceration occurs in patients on Olfen treatment, administration of the medicinal product should be discontinued.&nbsp;<br />&nbsp;<br />Skin reactions &nbsp;Serious, sometimes fatal, skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have very rarely been associated with the use of NSAIDs, including Olfen (see &ldquo;Undesirable effects&rdquo;). The risk to the patients appears to be greatest at the start of treatment, and the reaction mostly subsides within the first month of treatment. Olfen should be discontinued at the first sign of skin rash, mucosal lesions or other signs of hypersensitivity. &nbsp;As with other NSAIDs, diclofenac can in rare cases result in allergic reactions, including anaphylactic/anaphylactoid reactions, even without prior exposure to the medicinal product. &nbsp;<br />&nbsp;<br />Masked signs of infection &nbsp;Due to its pharmacodynamic properties, Olfen &ndash; in common with other NSAIDs &ndash; may mask the signs and symptoms of an infection.&nbsp;<br />&nbsp;<br />Precautions &nbsp;General &nbsp;The concomitant use of Olfen and systemic NSAIDs, such as selective cyclooxygenase-2 inhibitors, must be avoided since there is a potential for additive undesirable effects (see &ldquo;Interactions&rdquo;).&nbsp;<br />&nbsp;<br />Due to basic medical considerations, caution is advised in elderly patients. In frail elderly patients or those with a low body weight in particular, it is advisable to administer the lowest effective dose. &nbsp;The sodium metabisulfite contained in the ampoules can in isolated cases also trigger hypersensitivity reactions. &nbsp;Respiratory effects (pre-existing asthma) &nbsp;Reactions to NSAIDs, such as exacerbated asthma (referred to as analgesic intolerance/analgesic asthma), angioedema or urticaria, are more common in patients with asthma, seasonal allergic rhinitis, nasal mucosa swelling (e.g. nasal polyps), chronic obstructive pulmonary disease or chronic respiratory tract infection (especially if associated with allergic rhinitis-like symptoms) than in other patients. Therefore, special caution should be exercised in these patients (readiness for an emergency). This also applies to patients who experience allergic reactions to other substances in the form of skin rash, pruritus or urticaria, for instance. &nbsp;Particular caution is necessary when administering Olfen parenterally to patients who have bronchial asthma, since the symptoms can be exacerbated as a result. Gastrointestinal effects &nbsp;As with all NSAIDs, including diclofenac, close medical monitoring is imperative and particular caution required when prescribing Olfen to patients with symptoms indicative of gastrointestinal (GI) disorders, or to patients with a history of gastric or intestinal ulceration, bleeding or perforation (see &ldquo;Undesirable effects&rdquo;). The risk of GI bleeding is greater at higher NSAID doses as well as in patients with a history of ulceration, particularly if additionally complicated by bleeding or perforation, and in the elderly. &nbsp;To reduce the risk of GI toxicity in patients with a history of ulceration, particularly if additionally complicated by bleeding or perforation, and in the elderly, treatment should be initiated and maintained at the lowest effective dose. &nbsp;Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these patients, as well as for patients requiring concomitant low-dose acetylsalicylic acid (ASA) or other medicinal products that may increase the gastrointestinal risk. Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, antiplatelet agents or selective serotonin reuptake inhibitors (see &ldquo;Interactions&rdquo;).&nbsp;<br />&nbsp;<br />Hepatic effects &nbsp;<br />Close medical monitoring is necessary when prescribing Olfen to patients with impaired hepatic function, since their condition may be exacerbated (see &ldquo;Undesirable effects&rdquo;). &nbsp;As with other NSAIDs, including diclofenac, the levels of one or more liver enzymes may increase during treatment with Olfen. This has been reported very commonly (in approx. 15% of patients) in clinical trials of diclofenac, but is rarely accompanied by clinical symptoms. In the majority of these cases, the increases were marginal. Moderate increases (&ge; 3‒&lt; 8 times the upper limit of normal) were observed commonly (in 2.5%), whereas the incidence of marked increases (&ge; 8 times the upper limit of normal) remained at approximately 1%. In the aforementioned clinical trials, 0.5% of patients had clinically manifest liver damage in addition to elevated liver enzyme levels. The increases in the enzyme levels were generally reversible after discontinuation of the medicinal product. &nbsp;Hepatitis can occur during diclofenac treatment without prodromal symptoms. Olfen is to be used with caution in patients with hepatic porphyria, since it can induce an attack.&nbsp;<br />&nbsp;<br />Renal effects &nbsp;Given that prostaglandins play an important role in maintaining renal perfusion, oedema and hypertension result commonly (in 1%&minus;10%) from prolonged periods of treatment with high doses of NSAIDs, including diclofenac. &nbsp;Particular caution is required in patients with impaired cardiac or renal function, in patients with a history of hypertension, in elderly patients, in patients also taking diuretics or medications that have a considerable influence on renal function, as well as in patients with pronounced fluid deficiency in the extracellular space due to any cause, e.g. before or after a major surgical procedure (see &ldquo;Contraindications&rdquo;). Monitoring of renal function is recommended as a precautionary measure if Olfen is used in such cases. The patient usually returns to his/her pretreatment condition on discontinuation of treatment.&nbsp;<br />&nbsp;<br />Cardiovascular effects &nbsp;Treatment with NSAIDs, including diclofenac, can be associated with a slight, increased risk of severe cardiovascular thrombotic events (including myocardial infarction and stroke), especially at high doses and over prolonged periods. &nbsp;Treatment with Olfen is generally not recommended in patients with existing cardiovascular disease (cardiac failure, existing ischaemic heart disease, peripheral arterial occlusive disease) or uncontrolled hypertension. If necessary, patients with existing cardiovascular disease, uncontrolled hypertension or significant risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking) should not be treated with Olfen until after a careful assessment and if treatment is continued for more than 4 weeks they should not receive doses exceeding 100 mg/day. &nbsp;As the cardiovascular risk factors of diclofenac can increase with the dose and duration of administration, the lowest effective daily dose should be used for the shortest possible duration.&nbsp;<br />The patient&#39;s need for symptomatic relief and the response to the treatment should be reviewed periodically, particularly if the treatment is continued for more than 4 weeks. &nbsp;The patient should be alert to signs and symptoms of serious arterial thromboembolic events (e.g. chest pain, shortness of breath, weakness, slurred speech), which can occur without warning. Patients should be instructed to consult a doctor immediately in the case of such events. &nbsp;<br />&nbsp;<br />Haematological effects &nbsp;Monitoring of the blood count is recommended during long-term treatment with Olfen, as with other NSAIDs. &nbsp;Like other NSAIDs, Olfen can also temporarily inhibit platelet aggregation. Patients with a coagulation disorder should be closely monitored.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The following interactions have been reported with Olfen ampoules and/or other pharmaceutical forms of diclofenac. Reported interactions to be considered &nbsp;CYP2C9 inhibitors Caution is recommended when administering diclofenac with CYP2C9 inhibitors (e.g. voriconazole). Significant increases in the peak plasma concentration of diclofenac and an overall increase in total exposure to diclofenac can occur. &nbsp;CYP2C9 inducers &nbsp;Caution is recommended when administering diclofenac with CYP2C9 inducers (e.g. rifampicin). A significant decrease in plasma concentrations and exposure may occur as a result of diclofenac. Lithium &nbsp;If used concomitantly, diclofenac can raise the plasma concentration of lithium. Monitoring of serum lithium concentrations is recommended. &nbsp;Digoxin &nbsp;If used concomitantly, diclofenac can raise the plasma concentration of digoxin. Monitoring of serum digoxin concentrations is recommended. &nbsp;Diuretics and antihypertensive agents &nbsp;As with other NSAIDs, co-administration of diclofenac with diuretics or antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE) inhibitors) can reduce their antihypertensive activity. Such a combination should therefore be administered with caution, and patients, the elderly in particular, should have their blood pressure monitored regularly. Patients should be adequately hydrated, and attention should be paid to monitoring renal function after initiating concomitant therapy as well as periodically thereafter, particularly when using diuretics and ACE inhibitors, due to the increased risk of nephrotoxicity (see &ldquo;Warnings and precautions&rdquo;). Ciclosporin and Tacrolimus &nbsp;<br />Diclofenac, like other NSAIDs, can increase the nephrotoxicity of ciclosporin and tacrolimus due to its effects on renal prostaglandins. Therefore, it should be given at doses lower than those given to patients not receiving ciclosporin or tacrolimus. &nbsp;Medicinal products known to cause hyperkalaemia &nbsp;Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim can be associated with elevated plasma potassium levels, which should therefore be checked frequently (see &ldquo;Warnings and precautions&quot;). &nbsp;Quinolone antibiotics There have been isolated reports of convulsions which were possibly attributable to the concomitant use of quinolones and NSAIDs. &nbsp;Foreseeable interactions to be considered &nbsp;Other NSAIDs and corticosteroids &nbsp;Co-administration of diclofenac with other systemic NSAIDs or corticosteroids can increase the frequency of adverse gastrointestinal reactions (See &ldquo;Warnings and precautions&rdquo;). &nbsp;Anticoagulants and antiplatelet agents &nbsp;Caution is recommended since concomitant administration could increase the risk of bleeding (see &ldquo;Warnings and precautions&rdquo;). &nbsp;Although clinical trials do not appear to suggest that diclofenac influences the effect of anticoagulants, there have been reports of an increased risk of bleeding in patients receiving diclofenac and anticoagulants concomitantly. Such cases therefore need to be monitored closely. Selective serotonin reuptake inhibitors (SSRIs) &nbsp;Concomitant administration of systemic NSAIDs, including diclofenac, and SSRIs can increase the risk of gastrointestinal bleeding (see &ldquo;Warnings and precautions&rdquo;). &nbsp;Antidiabetic agents &nbsp;Clinical trials have demonstrated that diclofenac can be given together with oral antidiabetic agents without influencing their clinical effect. However, there have been isolated reports of hypoglycaemic and hyperglycaemic effects following administration of diclofenac, requiring the dosage of the antidiabetic agents to be adjusted. &nbsp;For this reason, it is advisable to monitor the glycaemia level as a precautionary measure during combination therapy. &nbsp;There have also been isolated reports of metabolic acidosis when diclofenac was administered together with metformin, especially in patients with pre-existing impaired renal function. Methotrexate &nbsp;Caution is advised when administering NSAIDs, including diclofenac, less than 24 hours before or after treatment with methotrexate, since the blood levels of methotrexate may rise and the toxicity of methotrexate may be increased. &nbsp;Phenytoin If phenytoin is used together with diclofenac, monitoring of the plasma phenytoin concentration is recommended, as an increase in phenytoin exposure can be expected.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Fertility &nbsp;Diclofenac can impair female fertility and thus is not recommended in women who wish to conceive. In women who are having difficulty conceiving or who are undergoing fertility tests, discontinuation of diclofenac should be considered. &nbsp;In animals, impairment of male fertility cannot be ruled out based on the corresponding data (see &ldquo;Preclinical data&rdquo;). The relevance of these findings to humans is not clear. &nbsp;Pregnancy &nbsp;Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryofoetal development. Data from epidemiological studies suggest that the risk of miscarriage, as well as cardiac malformations and gastroschisis, is higher after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with the dose and duration of therapy. &nbsp;In animals, administration of a prostaglandin synthesis inhibitor has been found to increase pre- and post-implantation loss and embryofoetal lethality. In addition, increased incidences of various malformations, including cardiovascular abnormalities, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenesis phase (see &ldquo;Preclinical data&rdquo;). Diclofenac should not be given during the first and second trimesters of pregnancy unless absolutely necessary. If diclofenac is used by a woman attempting to conceive, or during the first or second trimester of pregnancy, the dose and duration of treatment should be kept to a minimum. &nbsp;Diclofenac is contraindicated during the third trimester of pregnancy. All prostaglandin synthesis inhibitors can: &nbsp;‒ expose the foetus to the following risks: &nbsp;o Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension; see also &ldquo;Preclinical data&rdquo;); &nbsp;o Impaired renal function, which may progress to renal failure with oligohydramnios; &nbsp;‒ expose the mother and child to the following risks: o Possible prolongation of bleeding time, an inhibitory effect on platelet aggregation which may occur even at very low doses; &nbsp;o Inhibition of uterine contractions resulting in delayed or prolonged labour. &nbsp;Lactation &nbsp;As with other NSAIDs, small amounts of diclofenac are excreted in human milk. As a precaution, therefore, diclofenac should not be used in women who are breast-feeding. If treatment is essential, the infant should be switched to bottle feeding.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Patients who experience visual disturbances, drowsiness, dizziness, somnolence or other central nervous system disorders while taking Olfen should refrain from driving or using machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The undesirable effects listed below include those reported with diclofenac ampoules and/or other pharmaceutical forms of diclofenac used for short-term or long-term treatment. &nbsp;<br />Frequencies &nbsp;Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000). &nbsp;Infections and infestations &nbsp;Very rare: Abscesses at the injection site. &nbsp;Blood and lymphatic system disorders &nbsp;Very rare: thrombocytopenia, leukopenia, anaemia (including haemolytic and aplastic anaemia), agranulocytosis. &nbsp;Immune system disorders &nbsp;Rare: hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock). &nbsp;Very rare: angioedema (including facial oedema). &nbsp;Psychiatric disorders &nbsp;Very rare: disorientation, depression, insomnia, nightmares, irritability, psychotic disorder. Nervous system disorders &nbsp;Common: headache, drowsiness. &nbsp;Rare: somnolence. &nbsp;Very rare: paraesthesia, memory disorders, convulsion, anxiety, tremor, aseptic meningitis, dysgeusia, cerebrovascular event. &nbsp;Eye disorders &nbsp;Very rare: visual disturbance, amblyopia, diplopia. &nbsp;Ear and labyrinth disorders &nbsp;Common: vertigo. &nbsp;Very rare: tinnitus, impaired hearing. &nbsp;Cardiac disorders &nbsp;Uncommon*: myocardial infarction, cardiac failure, palpitations, chest pain. &nbsp;Vascular disorders &nbsp;Very rare: hypertension, vasculitis. &nbsp;Respiratory, thoracic and mediastinal disorders &nbsp;Rare: asthma (including dyspnoea). &nbsp;Very rare: pneumonitis. &nbsp;Gastrointestinal disorders &nbsp;Common: nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, flatulence, decreased appetite. &nbsp;Rare: gastritis, gastrointestinal bleeding, haematemesis, haemorrhagic diarrhoea, melaena, gastrointestinal ulcer (with or without bleeding, gastrointestinal stenosis or perforation, which may lead to peritonitis). &nbsp;Very rare: colitis (including haemorrhagic colitis, ischaemic colitis and exacerbation of ulcerative colitis or Crohn&rsquo;s disease), constipation, stomatitis, glossitis, oesophageal disorder, intestinal diaphragm disease, pancreatitis. &nbsp;Hepatobiliary disorders &nbsp;<br />Common: transaminases increased. &nbsp;Rare: hepatitis, jaundice, hepatic dysfunction. &nbsp;Very rare: fulminant hepatitis, hepatic necrosis, hepatic failure. &nbsp;Skin and subcutaneous tissue disorders &nbsp;Common: skin rash. Rare: urticaria. &nbsp;Very rare: bullous dermatitis, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, Lyell&rsquo;s syndrome (toxic epidermal necrolysis), exfoliative dermatitis, alopecia, photosensitivity, purpura, Henoch-Schonlein purpura, pruritus. &nbsp;Renal and urinary disorders &nbsp;Common: fluid retention, oedema, hypertension. &nbsp;Very rare: acute renal damage (acute renal failure), haematuria, proteinuria, tubulointerstitial nephritis, nephrotic syndrome, renal papillary necrosis. &nbsp;Administration site reactions &nbsp;Common: injection site reaction, injection site pain, injection site induration. &nbsp;Rare: oedema, injection site necrosis. &nbsp;* The frequency reflects data from long-term treatment with a high dose (150 mg/day). &nbsp;Meta-analyses of controlled clinical trials and pharmaco-epidemiological data suggest that the use of diclofenac, particularly at high doses (150 mg daily) and over prolonged periods, can be associated with an increased risk of arterial thromboembolic events (e.g. myocardial infarction or stroke) (see &ldquo;Warnings and precautions&rdquo;). &nbsp;Effects on vision &nbsp;Visual disturbances, such as visual deterioration, blurred vision and diplopia, seem to be a class effect of NSAIDs and are normally reversible after discontinuation of therapy. A probable mechanism for visual disturbances is an inhibition of the synthesis of prostaglandin and other similar substances that may alter the regulation of retinal blood pressure and may lead to possible changes in vision. If such symptoms occur during treatment with diclofenac, an ophthalmological examination should be considered to exclude other causes.&nbsp;<br />&nbsp;<br />To report any side effect(s): The National Pharmacovigilance and Drug Safety Centre (NPC) &nbsp; &nbsp; &nbsp; &nbsp; &bull; Fax: +966-11-205-7662 &nbsp; &nbsp; &nbsp; &nbsp; &bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. &nbsp; &nbsp; &nbsp; &nbsp; &bull; Toll free phone: 8002490000 &nbsp; &nbsp; &nbsp; &nbsp; &bull; E-mail: npc.drug@sfda.gov.sa &nbsp; &nbsp; &nbsp; &nbsp; &bull; Website: www.sfda.gov.sa/npc &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Symptoms There is no typical clinical picture that results from diclofenac overdose. Overdose can cause&nbsp;<br />symptoms such as vomiting, gastrointestinal bleeding, diarrhoea, drowsiness, tinnitus or convulsions. Acute renal failure and hepatic damage may occur in the event of severe intoxication. Therapeutic measures Treatment for acute intoxication from NSAIDs, including diclofenac, essentially comprises supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment should be introduced in response to complications such as hypotension, renal failure, convulsions, gastrointestinal symptoms and respiratory depression. Specific measures such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs, including diclofenac, due to their high protein-binding capacity and extensive metabolisation.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">ATC code: M01AB05 Mechanism of action/Pharmacodynamics Olfen ampoules contain the sodium salt of diclofenac, a non-steroidal active substance with pronounced antirheumatic, anti-inflammatory, analgesic and antipyretic properties. The inhibition of prostaglandin biosynthesis demonstrated experimentally is regarded as essential to the mechanism of action. Prostaglandins play a considerable part in the development of inflammation, pain and fever. At concentrations equivalent to those reached in humans, Olfen does not suppress the in vitro biosynthesis of proteoglycans in cartilage. Clinical efficacy In the treatment of rheumatic diseases, the anti-inflammatory and analgesic properties give rise to a marked improvement in symptoms such as pain at rest, pain on movement, morning stiffness, joint swelling, as well as an increase in functionality. In post-traumatic and postoperative inflammation, Olfen rapidly decreases spontaneous and movement-induced pain, and reduces inflammatory swelling and wound oedema. &nbsp;If combined with opioids as a treatment for postoperative pain, Olfen significantly reduces the need for opioids. &nbsp;In clinical trials, the pronounced analgesic activity was also observed in moderate and severe nonrheumatic pain with an onset of effect within 15-30 minutes. Olfen was also found to have a favourable influence on the symptoms of migraine attacks. &nbsp;Olfen ampoules are suitable as initial treatment for inflammatory and degenerative rheumatic diseases in particular, as well as for treatment of inflammatory, non-rheumatic pain.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption &nbsp;After intramuscular injection of 75 mg diclofenac, mean peak plasma concentrations of 2.5 &mu;g/ml are reached after about 20 minutes. If diclofenac is given as an intravenous infusion of 75 mg for 2&nbsp;hours, the mean peak plasma concentrations reach approx. 1.9 &mu;g/ml. More rapid infusions result in higher peak plasma concentrations; slower infusions produce plateau concentrations proportional to the infusion rate after 3&minus;4 hours. &nbsp;Conversely, the plasma concentrations drop rapidly once they reach their peak following intramuscular injection or administration of gastro-resistant tablets or suppositories. &nbsp;The area under the concentration curve (AUC) after intramuscular or intravenous administration of an equivalent dose is about twice as large as it is following oral or rectal administration, since only about half of the active substance undergoes first-pass hepatic metabolism after oral or rectal administration. &nbsp;The kinetics do not change after repeat administration. Accumulation does not result when the recommended dosage intervals are maintained. &nbsp;Distribution &nbsp;99.7% of diclofenac is bound to serum proteins, mainly to albumin (99.4%). &nbsp;The apparent volume of distribution can be calculated and is 0.12&minus;0.17 L/kg, accordingly. &nbsp;Diclofenac enters the synovial fluid. Here, maximum concentrations are measured 2&minus;4 hours after the peak plasma concentrations have been reached. The apparent elimination half-life in synovial fluid is 3&minus;6 h. As early as two hours after the peak plasma concentration isreached, the concentration of active substance in synovial fluid is higher than in the plasma and remains higher for up to 12 h. A low concentration of diclofenac (100 ng/ml) was detected in the breast milk of one nursing mother. The estimated amount ingested by an infant consuming breast milk is equivalent to a dose of 0.03 mg/kg/day. Metabolism Biotransformation takes place partly through glucuronidation of the intact molecule, but mainly through single and multiple hydroxylation and methoxylation. This results in several phenolic metabolites (3&rsquo;-hydroxy-, 4&rsquo;-hydroxy-, 5-hydroxy-, 4&rsquo;,5-dihydroxy- and 3&rsquo;-hydroxy-4&rsquo;-methoxydiclofenac), which are then extensively conjugated to glucuronic acid. Two of these phenolic metabolites are pharmacologically active, albeit significantly less so than diclofenac. Elimination The active substance is eliminated from the plasma with a systemic clearance of 263 &plusmn; 56 ml/min (x &plusmn; SD). The terminal half-life is 1&minus;2 h. Four of the metabolites, including the two active metabolites, also have a short half-life of 1&minus;3 h. The virtually inactive metabolite 3&rsquo;-hydroxy-4&rsquo;methoxy-diclofenac has a much longer half-life. Approximately 60% of the administered dose is eliminated via the kidneys in the form of metabolites and less than 1% as unchanged substance. The remainder of the dose is eliminated as metabolites with the bile in the faeces. Linearity/Non-linearity The relationship between the plasma concentrations and dose is linear. Kinetics in special patient groups &nbsp;<br />No relevant age-dependent differences have been observed in terms of absorption, metabolism or excretion of the medicinal product. In elderly patients, however, a 15-minute intravenous infusion produced plasma concentrations that were 50% higher than those expected based on the results obtained with young, healthy subjects. &nbsp;In patients with impaired renal function, no accumulation of unchanged active substance can be inferred from the kinetics of a single dose in the usual dosage regimen. When creatinine clearance is less than 10 ml/min, the theoretical steady-state plasma level of the metabolites is approximately four times higher than in healthy people. Nevertheless, the metabolites are ultimately eliminated via the bile. In cases of impaired hepatic function (chronic hepatitis, compensated hepatic cirrhosis), the kinetics and metabolism of diclofenac are the same as in patients with a healthy liver.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non-clinical data from studies of safety pharmacology, acute toxicity and repeated dose toxicity as well as from genotoxicity, mutagenicity and carcinogenicity studies with diclofenac reveal no special hazard for humans at the intended therapeutic dosages. The increased incidence of lymphoma (thymus) in mice, and the increased incidence of subcutaneous fibromas, fibroadenomas (mammary gland) or C-cell adenomas (thyroid) in rats, were all within the historical control range of the laboratory for the tested animal strain and were classified as coincidental. &nbsp;All the toxicity studies performed on rats reported hypertrophy of the mesenteric lymph nodes or lymphadenitis with reactive hyperplasia. These changes were accompanied by neutrophilia, which was also observed in studies on monkeys. These reactions are suspected to be secondary to the ulcers observed in the gastrointestinal tract. In a 2-year study in rats treated with diclofenac, a dose-dependent increase in thrombotic vascular occlusions in the heart was reported. &nbsp;Additional studies suggested that fertility was influenced (reduced testosterone levels and decreased epididymal and testicular weights combined with histopathological changes) in rats given repeated oral doses of diclofenac (&gt; 1 mg/kg body weight). Similar effects were also observed in the F1 generation after doses of &ge;1.25 mg/kg in a 2-generation study. In dogs, a daily subcutaneous dose of 2 mg/kg diclofenac sodium resulted in an increased sperm count. Other studies report that the percentage of mating female rats was reduced following repeated diclofenac doses of &ge;0.5 mg/kg. Hence, an influence on both male and female fertility cannot be ruled out. &nbsp;Diclofenac crosses the placental barrier in rodents. The administration of NSAIDs (including diclofenac) inhibited ovulation in rabbits, implantation and placentation in rats, and premature closure of the ductus arteriosus in pregnant rats. In rats, maternal toxic doses of diclofenac were linked to dystocia, prolonged gestation, decreased foetal survival and delayed intrauterine growth. The minimal effects of diclofenac on reproduction parameters and birth, as well as on closure of the ductus arteriosus in utero, represent the pharmacological activity of this class of prostaglandin synthesis inhibitors (see &ldquo;Contraindications&rdquo; and &ldquo;Pregnancy/Lactation&rdquo;). &nbsp;Teratogenicity (cleft palate) was observed at the maternal toxic dose of 4 mg/kg in a study of mice. No teratogenic effects were reported in rats and rabbits treated with doses up to the maternal toxic&nbsp;<br />level. Delayed ossification and reduced foetal weight in one study of rabbits were the only changes observed in these tests. &nbsp;At maternal toxic doses, perinatal and postnatal development of the progeny was adversely affected (for fertility see above, as well as birth weight and delayed postnatal growth).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">N-acetylcysteine, disodium edetate, macrogol 400, propylene glycol, sodium hydroxide, water for injections.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The Olfen 75 IM generally should not be mixed with other solutions for injection. &nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 months. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Period of use &nbsp;The preparation must be administered immediately after reconstitution; discard any unused solution. Special storage instructions &nbsp;Do not store above 30&deg;C. &nbsp;Store the Olfen 75 IM in the original package in a dry place. &nbsp;Keep out of the sight and reach of children.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The product is filled into 2 ml amber (brown) glass ampoules (hydrolytic class I), with white OPC (One Point Cut) point. &nbsp;Packs of 3 and 5 ampoules of 2 ml; hospital packs. Not all pack sizes may be marketed.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Acino Pharma AG, Liesberg (Switzerland)  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2018 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>